Clinical Trial

Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

Name: Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) — clinical trial record (NCT07509749)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GVHD

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the severe acute GVHD (graft-versus-host disease )

Trial Details

NCT Number	NCT07509749
Lead Sponsor	Daihong Liu
Conditions	GVHD, Acute, Stem Cell Transplant Complications
Enrollment	54 participants
Start Date	2025-06-30
Primary Completion	2027-12-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-03